Ahp72201
Oxcarbazepine Tablet, Film Coated
Product Images NDC 55154-2139
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 55154-2139). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure1)
The log-rank test was performed with a p-value of 0.0001. The table shows the time on trial from Day 2 (in days) for the treatment group, Oxcarbarspine, at Day 11.*
Figure 2: Kaplan-meier Estimates Of First Seizure Event Rate By Treatment Group (Figure2)
Figure 3: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure3)
The output above represents the results of a statistical test known as the log-rank test. The result shows a p-value of 0.0001, indicating a statistically significant difference between two groups of data. The table below the test result shows data points for time to exit (measured in days) for a treatment group with both high and low values. This output could be used for further analysis and interpretation related to survival analysis.*
Figure 4: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure4)
This appears to be a statistical analysis of a survival dataset using the log-rank test. The p-value of the test is 0.0001 indicating a statistically significant difference in survival between the groups being compared. The dataset includes time to exit in days and a treatment group labeled as "HIGH" and "LOW".*
Structural Formula (Structure)
Bag Label (Image 01)
Oxcarbazepine is a medication administered to prevent and reduce seizures in patients with epilepsy. The medication comes in a package with the National Drug Code 55154-2138-0 and contains 10 film-coated tablets with each tablet comprising 300mg of Oxcarbazepine USP. The instructions for use are provided in the product insert. The medication ought to be stored at temperatures advised in the instructions. Nonetheless, the American Health Packaging company warns against using the drug if the blister is torn. This packaging, identified by NDC # 31722-024, is supplied by Camber Pharmaceuticals. The product is supplied exclusively to institutions and not for individual consumer use to prevent the possibility of inadvertent harm to children. The Medication Guide should be dispensed to every patient who gets the drug, and it should be kept out of reach of children. The wholesaler name and location are also supplied by the drug manufacturer.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
